Volumetric Modulated Arc Therapy Research Articles

Dose compensation for decreased biological effective dose due to intrafractional interruption during radiotherapy: integration with a commercial treatment planning system.

While the biological effective dose (BED) has been used to estimate the damage to tumor cells in radiotherapy, BED does not consider intrafractional interruption (IFI) occurring during irradiation. We aim to develop a framework to evaluate the decrease in BED [ΔBED] and to create a plan compensating for the decrease by IFI.
Approach. ΔBED was calculated using a model based on the microdosimetric kinetic model (MKM) for four brain tumor cases treated using a volumetric-modulated arc therapy. Four biologically compensated plans (BCPs) were created in the treatment planning system by a single-time optimization using a base plan considering ΔBED created in in-house software and optimization objectives for the original clinically delivered plan to achieve a homogeneous BED distribution within the planning target volume (PTV). The BED-volume histogram was evaluated for non-compensated plan and BCP with different timepoint of interruption, a percentage of gantry rotation angle (GRA) before interruption in planned GRA,ηand duration of interruptionτ. Characteristics of the dose accumulation were analyzed for different collimator angle sets, Plan A (10°, 85°) and Plan B (45° and 315°), for the first case.
Main Results. Hot spots in the ΔBED distribution forη= 25%, 50%, and 75% were observed at superior-and-interior ends, central region, and peripheral region in PTV, respectively. These behaviors could be understood by characteristics of the MKM-based model producing maximum ΔBED at 50% of the dose accumulation. ΔBED50%ranged 4.5-6.6%, 5.0-7.3%, and 5.3-7.7% forτ= 60, 90, and 120 mins, respectively. Plan A showed fast dose accumulation at superior and inferior edges while slow on peripheries in the lateral dose profile. Plan B showed more homogeneous PD distributions than Plan A during irradiation.
Significance. The developed framework successfully evaluated and compensated for the decreased BED distribution.&#xD.

Multicriteria optimization achieves superior normal tissue sparing in volumetric modulated arc therapy for gastric cancer.

To evaluate the benefits of volumetric modulated arc therapy (VMAT) based on multicriteria optimization (MCO) for gastric cancer patients, particularly the protection of serial organs at risk (OARs) that overlap with the target volume. MCO and single-criterion optimization (SCO) VMAT plans were conducted among 30 gastric cancer patients, with a prescription dose of 50.4Gy delivered in 28 fractions. All treatment plans underwent review, and a comparison was made between the active planning time and different dose-volume parameters. Both the MCO and SCO VMAT plans achieved the target dose coverage, with no significant difference in the conformity index (CI) for the planning target volume (PTV), at median CI values of 0.887 and 0.891, respectively (P = 0.417). The MCO plans showed a slight but significant increase in the homogeneity index of the PTV, with a median increase of 0.029 (P < 0.001). Additionally, the MCO plans resulted in a lower D2% to the small intestine and duodenum, with reductions of 3.43Gy and 0.3Gy, respectively (P < 0.05). Furthermore, the Dmax to the small intestine correlated moderately with the overlapping volume between the small intestine and the target volume (ρ = 0.42, P = 0.023). Except for the mean dose to the liver, the MCO plans performed better in terms of dose indicators for other OARs. Moreover, compared to the SCO plans, the median active planning time in the MCO plans was significantly reduced by 53.2min (P < 0.0001). MCO can effectively help the physicians to quickly select an optimal treatment plan for patients with gastric cancer. It has been shown that MCO VMAT plans can significantly reduce the dose to OARs and shorten the active planning time, with acceptable target coverage. In addition, these plans take less dosimetric time, thereby streamlining the treatment planning process.

Radiation induced liver injury (RILI) evaluation using longitudinal computed tomography (CT) in image‐guided precision murine radiotherapy

AbstractPurposeWe aim to perform image‐guided, dose‐escalated, well‐controlled liver‐irradiated animal studies and subsequently evaluate radiation induced liver injury (RILI) using longitudinal CT.MethodsEighteen 6–8 weeks mice were divided into three groups: control, 15Gy and 30Gy irradiated groups. The animal protocol was approved by the animal care ethics committee of our institution. Precision radiotherapy started with CT simulation, followed by treatment planning using volumetric modulated arc therapy (VMAT), image guidance with cone beam CT (CBCT) and radiation delivery on a medical linear accelerator. Weekly CT was conducted on the same CT simulator using same scanning parameters. At the end of fifth week, all mice were sacrificed, and histological staining was performed. Body weight, liver volume, HU values and histogram distributions were analyzed.ResultsBody weight of irradiation groups was significantly reduced compared to that of the control group (p&lt;0.05). Liver volume in irradiated groups was reduced too. The average liver HU was significantly reduced in irradiated groups (HU mean = 62±3, 48±6, and 36±8 for the control, 15Gy and 30Gy respectively; p control vs. 15Gy &lt; 0.05, p control vs. 30Gy &lt; 0.05). A linear relationship between liver HU and radiation dose was found. Furthermore, HU histogram changes with time and dose showed not only density but also structure might be affected by radiation. HE and Masson Trichrome staining confirmed histological change and increased collagen deposition in irradiated liver.ConclusionLongitudinal unenhanced CT is a useful imaging tool to evaluate the severity and progression of radiation induced liver injury.

Improvement of plan quality in whole-breast radiation following BCS using feasibility DVH by less-experienced planners.

Variability in plan quality of radiotherapy is commonly attributed to the planner's skill rather than technological parameters. While experienced planners can set reasonable parameters before optimization, less experienced planners face challenges. This study aimed to assess the quality of volumetric-modulated arc therapy (VMAT) in patients with left-sided breast cancer following breast-conserving surgery. Twenty-eight patients requiring whole-breast irradiation were randomly selected for inclusion. Each patient underwent two VMAT treatment plans: one optimized by an experienced planner (VMAT-EXP group) and the other designed by a less experienced planner using feasibility dose-volume histogram (FDVH) parameters from PlanIQ (VMAT-FDVH group). Both plans aimed to deliver a prescription dose of 50Gy in 25 fractions to the planning target volume (PTV). Dosimetry parameters for the PTV and organs at risk (OARs) were compared between the two groups. Both the VMAT-EXP and VMAT-FDVH groups met the clinical plan goals for PTV and OARs. VMAT-FDVH demonstrated a PTV coverage and homogeneity comparable to those of VMAT-EXP. Compared to VMAT-EXP plans, VMAT-FDVH plans resulted in a significant reduction in the mean ipsilateral lung dose, with an average decrease of 0.9Gy (8.5Gy vs. 7.6Gy, P < 0.001). The V5Gy and V20Gy of the ipsilateral lung were also reduced by 3.2% and 1.8%, respectively. Minor differences were observed in the heart, contralateral lung, breast, and liver. Personalized objectives derived from the feasibility DVH tool facilitated the generation of acceptable VMAT plans. Less experienced planners achieved lower doses to the ipsilateral lung while maintaining adequate target coverage and homogeneity. These findings suggest the potential for the effective use of VMAT in in patients with left-sided breast cancer following breast-conserving surgery, especially when guided by feasibility DVH parameters.

A comparative dosimetric evaluation of dynamic conformal arc therapy and volumetric modulated arc therapy for lung stereotactic body radiotherapy

PurposeThis study assesses the viability of utilizing dynamic conformal arc therapy (DCAT) as an alternative to volumetric-modulated arc therapy (VMAT) in stereotactic body radiation therapy (SBRT) for lung cancer, with a focus on four-dimensional computed tomography (4DCT) in free-breathing conditions. Materials and methodsWe selected four non-small cell lung cancer (NSCLC) patients who had previously undergone VMAT SBRT and re-planned their treatment using DCAT. We compared the DCAT and VMAT plans based on dose distribution, conformity index (CI), homogeneity index (HI), gradient index (GI), and total monitor units (MUs). Quality assurance (QA) assessments for both plans were conducted using the Octavius 4D system (PTW, Freiburg, Germany). ResultsThe results showed that CIPaddick was 0.80 ± 0.06 and 0.79 ± 0.04 (p-value >0.05), HI was 1.16 ± 0.03 (p-value <0.05) and 1.07 ± 0.02, GI was 3.91 ± 0.05 and 3.40 ± 0.05 (p-value <0.05), and MU was 1880.42 ± 135.19 and 5020.82 ± 188.03 for DCAT and VMAT, respectively (p-value <0.05). The average gamma passing rate exceeded 95 % with a 2 %/2 mm criteria. The dose distribution displayed remarkable similarity between DCAT and VMAT. ConclusionThe DCAT technique exhibits the capacity to deliver PTV dose distributions comparable to those achieved with VMAT, while significantly reducing treatment duration.

A StarGAN and transformer-based hybrid classification-regression model for multi-institution VMAT patient-specific quality assurance.

The field of artificial intelligence (AI)-based patient-specific quality assurance (PSQA) for volumetric modulated arc therapy (VMAT) faces challenges in terms of developing general models across institutions due to the prevalence of multi-institution data collection and multivariate heterogeneity. Building a general model that is capable of handling diverse multi-institution data is critical for enabling large-scale integration and analysis. This study aims to develop a star generative adversarial network (StarGAN) and transformer-based hybrid classification-regression PSQA framework to address unification of heterogeneous data from different institutions. A StarGAN and transformer-based hybrid classification-regression model was developed as a general PSQA framework to predict gamma passing rates (GPRs) and classify quality assurance (QA) results as "Pass" or "Fail" at multiple institutions. A total of 1815 VMAT plans were collected from eight institutions to develop the general PSQA framework and perform clinical commissioning and implementation. Among them, 20 independent clinical plans from each of eight institutions, for a total of 160 plans, were used for the clinical commissioning, and 205 new clinical plans from eight institutions were used for clinical implementation. For the 3%/3, 3%/2, and 2%/2mm gamma criteria, the sensitivity of the proposed PSQA framework with pretraining was 90.13%, 92.03%, and 95.84%, respectively, while the specificity was 76.01%, 76.12%, and 85.34%, respectively. The mean absolute errors (MAEs) of the proposed PSQA framework with pretraining were 1.36%, 2.37%, and 3.96%, respectively, while the root-mean-square errors (RMSEs) were 2.31%, 3.89%, and 5.17%, respectively. The results demonstrated visible improvement at multiple institutions. For clinical commissioning, the deviations between the predicted and measured results were all within 3% for 3%/3 and 3%/2mm at eight institutions. For clinical implementation, all failure plans were correctly identified by the proposed PSQA framework. The general PSQA framework enables diverse clinical data sources to be handled to achieve enhanced model performance and generalizability, and provides a solution to the unification of heterogeneous data from different institutions to construct robust QA models. This approach can be clinically deployed for VMAT QA.

Interpreting the patterns of local failure following postoperative volumetric-modulated arctherapy in oral cavity and oropharynx cancers: Impact of the different methods of analysis

PurposeIntensity-modulated radiation therapy or volumetric-modulated arctherapy is nowadays the recommended radiation technique for the treatment of head and neck cancers. However, by providing a significant dose gradient between target volumes and organs at risk, there is a risk of target missing and thus recurrence in case of inadequate delineation. It is therefore necessary to determine the origin of these recurrences to improve clinical practice. Over the past years, different methods have been described for the analysis of recurrences. Using the patterns of failure of patients with oral cavity and oropharynx carcinoma, treated with postoperative volumetric-modulated arctherapy in our institution, the purpose of this work was to analyse the sites of local recurrences and to evaluate the disparity in the classification of recurrences when different methods were used. Material and methodsBetween 2011 and 2019, 167 patients who underwent postoperative volumetric-modulated arctherapy for oral cavity or oropharyngeal cancers were included (60 and 40 % respectively). Two or three dose levels were prescribed (54Gy, 59.4/60Gy±66Gy). Local recurrence occurred in 17 patients (10.2 %). We assessed the patterns of local recurrences according to four methods: 1/ volume-based method using the volume overlap between the recurrence volume and initial target volumes; 2/ volume-based method of overlap between the recurrence volume and the 95 % treatment isodose; 3/ point-based method using the position of the barycentre of the recurrence volume; 4/ combined centroid method classifying recurrences according to both the initial target volumes and dose distribution. Each case was reviewed to make a clinical judgment on these classifications and assessed them as “appropriate”, “possible”, or “inappropriate”. ResultsFor the volume-based method using overlap between the recurrence volume and the initial clinical target volume, this classification was clinically judged as inappropriate in 11 out of 17 cases (65 %). For the volume-based method using overlap between the recurrence volume and the 95 % prescribed isodose, this classification was clinically judged as appropriate in 15 out of 17 cases (88 %). For the point-based method, this classification was clinically judged as appropriate in 14 out of 17 cases (82 %). Thirteen out of 17 local recurrences had the same classification between this point-based method and the volume-based method of overlap between the recurrence volume and the 95 % prescribed isodose. For the combined centroid method, among 17 local recurrences nine were classified as type A, two as type B, two as type C, three as type D and one as type E. This classification was clinically judged as appropriate in 15 out of 17 cases (88 %). Only five out of 17 of the local recurrences were classified the same way according to the four different methods (29 %). ConclusionRecurrences that are “marginal” or “outfield” represent a major challenge for intensity-modulated radiation therapy/volumetric-modulated arctherapy quality assurance and improvement of delineation recommendations. To date, there are no published methods that give complete satisfaction.

Forecasting Daily Radiotherapy Patient Volumes in a Tertiary Hospital Using Autoregressive Integrated Moving Average (ARIMA) Models.

The purpose is to predict the volume of patients treated daily with radiotherapy using the autoregressive integrated moving average (ARIMA) model. In this retrospective study, data from the billing records detailing daily radiotherapy treatment sessions were extracted from the Hospital Information System and analyzed. The study included all patients treated from January 2004 to December 2022. The analysis was divided into two parts: First, the data were summarized using descriptive statistics. Second, time series forecasting with the implementation of an ARIMA model for estimating patient volumes. For the ARIMA modeling process, the Akaike Information Criterion (AIC) was used for classical model optimization. The Mean Absolute Percentage Error (MAPE) was used for evaluating between different models. Residual analysis was performed in each model using the Ljung-Box test, Jarque-Bera test, and heteroskedasticity test to identify autocorrelation, normal distribution, and variances that could undermine the reliability of the model. A total of 895,808 radiotherapy sessions were included in the study. The median number of radiotherapy sessions per day was 181 (150, 205). A clear transition to more modern radiotherapy equipment, particularly the Truebeam accelerator, was observed, indicating a growing dependency on advanced techniques such as volumetric-modulated arc therapy (VMAT), stereotactic body radiation therapy (SBRT), and stereotactic radiosurgery (SRS). The best ARIMA model predicted an increase in demand, projecting an average daily patient volume of 279.40 by 2030. The study highlights the need for advanced forecasting methodologies in healthcare resource planning and emphasizes the importance of considering environmental and external factors for effective and accurate resource allocation strategies.

Hypofractionated radiotherapy with simultaneous integrated boost for localized prostate cancer patients: effects on immune system and prediction of toxicity.

The other side of radiotherapy (RT), in addition to the cytotoxic effect, is the ability to modulate the immune system in terms of activation or suppression, also depending on the dose and fractionation delivered. This immune RT effect can be detected both locally in the irradiated tumor site and in the peripheral blood. The aim of this study was to assess the consequence of pelvic irradiation on peripheral immune cells and cytokine secretions in localized prostate cancer (PC) patients undergoing pelvic irradiation with a simultaneous moderately hypofractionated prostate/prostate bed boost by Volumetric Modulated Arc Therapy (VMAT). Furthermore, we analyzed whether there was a correlation between these peripheral immune parameters and acute and late genitourinary (GU) and gastrointestinal (GI) toxicity. Thirty-eight PC patients were treated with pelvis irradiation (dose per fraction 1.8 Gy) and simultaneous hypofractionated (median dose per fraction: 2.7 Gy) prostate/prostate bed boost. A longitudinal analysis was performed for 12 months on peripheral blood to assess changes in 9 different lymphocyte subpopulations by flow cytometry and 10 circulating cytokines by Multiplex Luminex assay and ELISA. Our analysis revealed that basal IFN-γ serum values were significantly lower in the definitive (curative intent for patients with prostate) patient group respect to the post-operative one. All the lymphocyte subsets and IFN-α, IFN-β and Il-2 peripheral concentrations displayed significant variations between the different time points considered. The immune cell population that suffers the greatest RT toxicity in the blood was B lymphocyte. We found an interesting correlation between basal TGF-β1 and late GU toxicity. In particular, TGF-β1 concentrations before RT were significantly higher in patients that experienced grade 2-3 of late GU toxicity, respect to grade 0-1. Exploring possible correlations between some clinical/biological findings and radiation planning parameters, we found no statistical significance. Our study analyzed, in the context of hypofractionated radiotherapy in prostate cancer, different parameters of the peripheral immune system. We have highlighted longitudinally the peripheral behavior of the different lymphocyte subpopulations and of a group of 10 cytokines during the first year after RT. One of the analyzed cytokines, such as TGF-β1, has proven to be promising predictive factor of severe late GU toxicity.

Dosimetric optimization for dynamic mixed beam arc therapy (DYMBARC).

Non-coplanarity and mixed beam modality could be combined to further enhance dosimetric treatment plan quality. We introduce dynamic mixed beam arc therapy (DYMBARC) as an innovative technique that combines non-coplanar photon and electron arcs, dynamic gantry and collimator rotations, and intensity modulation with photon multileaf collimator (MLC). However, finding favorable beam directions for DYMBARC is challenging due to the large solution space, machine component constraints, and optimization parameters, posing a highly non-convex optimization problem. To establish DYMBARC and solve the pathfinding challenge by employing direct aperture optimization (DAO) to determine the table angles and gantry angle ranges of photon and electron arcs for different clinically motivated cases. The method starts by generating a grid of beam directions based on user-defined resolutions along the gantry and table angle axes for each beam quality considered. Beam directions causing collisions or entering through the end of CT are excluded. For electrons, a fixed source-to-surface distance of 80cm is used to reduce in-air scatter. Electron beam energies with insufficient range to reach the target or beam directions impinging on the table before reaching the patient are excluded. The remaining beam directions form the pathfinding solution space. Promising photon and electron MLC-defined apertures, with associated monitor unit (MU) weights, are iteratively added using a hybrid-DAO algorithm. This algorithm combines column generation to add apertures and simulated annealing to further refine aperture shapes and weights. Apertures are added until the requested number of paths are formed and the user-defined maximum total gantry angle range is reached. Paths are resampled to a finer gantry angle resolution and subject to DAO for simultaneous optimization of beam intensities along the photon/electron arcs. Subsequent final dose calculation and MU weight reoptimization result in a deliverable DYMBARC plan. DYMBARC plans are created for three clinically motivated cases (brain, breast, and pelvis) and compared to DYMBARC variants: colli-DTRT (dynamic collimator trajectory radiotherapy) using non-coplanar photon arcs; and Arc-MBRT (mixed beam radiotherapy) using photons and electrons but restricted to coplanar setup. Additionally, a manually defined volumetric modulated arc therapy (VMAT) setup serves as a reference clinical technique. Dose distributions, dose-volume histograms, and dosimetric endpoints are evaluated. Dosimetric validation with radiochromic film measurements (gamma evaluation, 3% / 2mm (global), 10% dose threshold) is performed on a TrueBeam system in developer mode for one case. While maintaining similar target coverage and homogeneity, DYMBARC reduced mean doses to organs-at-risk compared to VMAT by an average of 3.2, 0.5, and 2.9Gy for the brain, breast, and pelvis cases, respectively. Similar or smaller mean dose reductions were observed for Arc-MBRT or colli-DTRT, compared to VMAT. Electron contributions to the mean planning target volume dose ranged from 2% to 34% for DYMBARC and from 11% to 40% for Arc-MBRT. Measurement validation showed>99.7% gamma passing rate. DYMBARC was successfully established using a dosimetrically optimized pathfinding approach, combining non-coplanarity with mixed beam modality. DYMBARC facilitated the determination of photon and electron contributions on a case-by-case basis, enhancing more personalized treatment modalities.

Dosimetric consequences of adapting the craniocaudal isocenter distance to daily patient position in craniospinal irradiation using volumetric modulated arc therapy.

In craniospinal irradiation, two or three isocenter groups along the craniocaudal axis are required to cover the long treatment target. Adapting the isocenter distance according to daily deviations in patient position is challenging because dosimetric hot or cold spots may occur in the field junction. The aim of this study was to quantify the effect of adapting the isocenter distance to patient position on the dose distribution of the field overlap region in craniospinal irradiation using partial-arc volumetric modulated arc therapy. The magnitude of isocenter distance deviations in craniocaudal direction was quantified by registering the setup images of 204 fractions of 12 patients to the planning images. The dosimetric effect of these deviations was determined by shifting the isocenters of the original treatment plan and calculating the resulting dose distribution. On fraction-level, deviations larger than 3mm caused more than 5 percentage point changes in the doses covering 2% (D2%) and 98% (D98%) of the junction volume in several patients. On treatment course-level, the changes in D2% and D98% of the junction volume were less than 5 percentage points in all cases except for one patient. Craniocaudal isocenter distance adaptation can be conducted provided that the mean isocenter distance deviation over the treatment course is within 3mm.

Implementing the optimized hippo-avoidance prophylactic cranial irradiation for limited-stage small cell lung cancer by tomotherapy and volumetric modulated arc therapy.

Hippo-avoidance prophylactic cranial irradiation (HA-PCI) requires a hippocampal avoidance zone expanded from hippocampus to ensure dose fall-off and compensate for setup errors. Most studies recommend a 5-mm margin, while it could be optimized to a 2-mm expansion. Here, we showed the details of optimized HA-PCI for limited-stage small cell lung cancer (LS-SCLC). This cohort study reviewed patients with LS-SCLC receiving optimized HA-PCI from August 2014 to June 2020 in the National Cancer Center of China. The hippo-related dose parameters were summarized. The comparison of the Hopkins Verbal Learning Test-Revised (HVLT-R) scores in different time points was conducted. The Kaplan-Meier method was used to calculate the survival rates. A total of 112 patients were included. The average doses of hippocampus and hippocampal avoidance zone were 6.80 Gy (IQR: 6.40-7.44) and 7.63 Gy (IQR: 7.14-8.39). No differences were observed in the two radiation techniques (tomotherapy [TOMO] vs. volumetric-modulated arc therapy [VMAT]). The decline of HVLT-R score remained in a low level and not significant in assessable patients (p = 0.095). With a median follow-up of 52 months (95% CI: 47.2-56.7), the 2-year overall survival and progression-free survival were 74.1% and 50.0%, respectively. Two intracranial recurrence lesions (2.3%) located <2 mm from the hippocampus. Optimized HA-PCI could achieve similar dose limitation by TOMO and VMAT techniques with favorable efficacy and minor toxicity.

Monte Carlo dose calculation for photon and electron radiotherapy on dynamically deforming anatomy.

Dose calculation in radiotherapy aims to accurately estimate and assess the dose distribution of a treatment plan. Monte Carlo (MC) dose calculation is considered the gold standard owing to its ability to accurately simulate particle transport in inhomogeneous media. However, uncertainties such as the patient's dynamically deforming anatomy can still lead to differences between the delivered and planned dose distribution. Development and validation of a deformable voxel geometry for MC dose calculations (DefVoxMC) to account for dynamic deformation in the dose calculation process of photon- and electron-based radiotherapy treatment plans for clinically motivated cases. DefVoxMC relies on the subdivision of a regular voxel geometry into dodecahedrons. It allows shifting the dodecahedrons' corner points according to the deformation in the patient's anatomy using deformation vector fields (DVF). DefVoxMC is integrated into the Swiss Monte Carlo Plan (SMCP) to allow the MC dose calculation of photon- and electron-based treatment plans on the deformable voxel geometry. DefVoxMC is validated in two steps. A compression test and a Fano test are performed in silico. Delta4 (for photon beams) and EBT4 film measurements in a cubic PMMA phantom (for electron beams) are performed on a TrueBeam in Developer Mode for clinically motivated treatment plans. During these measurements, table motion is used to mimic rigid dynamic patient motion. The measured and calculated dose distributions are compared using gamma passing rate (GPR) (3% / 2mm (global), 10% threshold). DefVoxMC is used to study the impact of patient-recorded breathing motion on the dose distribution for clinically motivated lung and breast cases, each prescribed 50Gy to 50% of the target volume. A volumetric modulated arc therapy (VMAT) and an arc mixed-beam radiotherapy (Arc-MBRT) plan are created for the lung and breast case, respectively. For the dose calculation, the dynamic deformation of the patient's anatomy is described by DVFs obtained from deformable image registration of the different phases of 4DCTs. The resulting dose distributions are compared to the ones of the static situation using dose-volume histograms and dose differences. DefVoxMC is successfully integrated into the SMCP to enable the MC dose calculation of photon- and electron-based treatments on a dynamically deforming patient anatomy. The compression and the Fano test agree within 1.0% and 0.1% with the expected result, respectively. Delta4 and EBT4 film measurements agree with the calculated dose by a GPR>95%. For the clinically motivated cases, breathing motion resulted in areas with a dose increase of up to 26.9Gy (lung) and up to 7.6Gy (breast) compared to the static situation. The largest dose differences are observed in high-dose-gradient regions perpendicular to the beam plane, consequently decreasing the planning target volume coverage (V95%) by 4.2% for the lung case and 2.0% for the breast case. A novel method for MC dose calculation for photon- and electron-based treatments on dynamically deforming anatomy is successfully developed and validated. Applying DefVoxMC to clinically motivated cases, we found that breathing motion has non-negligible impact on the dosimetric plan quality.

Dosimetric benefit and clinical feasibility of deep inspiration breath-hold and volumetric modulated arc therapy-based postmastectomy radiotherapy for left-sided breast cancer

To evaluate the dosimetric benefits and clinical feasibility of deep inspiratory breath-hold (DIBH) combined with volumetric modulated arc therapy (VMAT) in left-sided postmastectomy radiotherapy (PMRT). Eligible patients with left-sided breast cancer undergoing DIBH-based PMRT were prospectively included. Chest wall, supra/infraclavicular fossa, and/or internal mammary node irradiation (IMNI) were planned with a prescription dose of 43.5 Gy in 15 fractions. VMAT plans were designed on free breathing (FB)—and DIBH-CT to compare dosimetric parameters in heart, left anterior descending artery (LAD) and lung. Cone-beam computed tomography (CBCT) was performed before and after treatment to evaluate inter- and intra-fractional setup errors. Heart position and dose variations during treatment were estimated by fusing CBCT with DIBH-CT scans.Twenty patients were included with 10 receiving IMNI. In total, 193 pre-treatment and 39 pairs pre- and post-treatment CBCT scans were analyzed. The Dmean, Dmax, and V5−40 of the heart, LAD, and left lung were significantly lower in DIBH than FB (p < 0.05 for all), except for V5 of LAD (p = 0.167). The cardiopulmonary dosimetric benefits were maintained regardless of IMNI. The inter- and intra-fractional setup errors were < 0.3 cm; and the overall estimated PTV margins were < 1.0 cm. During treatment, the mean dice similarity coefficient of heart position and the mean ratio of heart Dmean between CBCT and DIBH-CT plans was 0.95 (0.88–1.00) and 100% (70.6–119.5%), respectively. DIBH-VMAT could effectively reduce the cardiopulmonary doses with acceptable reproducibility and stability in left-sided PMRT regardless of IMNI.

Optimising PTV margins in oesophageal cancer radiotherapy: Amodern radiotherapy planning, treatment delivery and verification approach - A single institutional analysis.

Radiotherapy plays a key role in the multidisciplinary management of oesophageal cancers across neoadjuvant, definitive and palliative settings. Improved precision in radiotherapy planning and delivery techniques have allowed treating disease with tighter margins reducing toxicity. In this study, we examine the appropriateness of current practice in defining the planning target volume (PTV). This is a single institutional retrospective study of patients who received radiotherapy for oesophageal cancers using volumetric modulated arc therapy (VMAT) during 2020. All cone-beam computerised tomography (CBCT) scans were reviewed to assess whether PTV expansions appropriately accounted for tumour motion and interfractional variation. Of the 27 patients, 2 (7%), 5 (19%) and 20 (74%) had cervical, thoracic and distal/gastro-oesophageal junction (GOJ) disease, respectively. 16 (59%) had adenocarcinoma and 9 (33%) had squamous cell carcinoma. 9 of 20 distal/GOJ patients were planned and treated according to the institutional stomach filling protocol. 521/528 (98.7%) CBCTs demonstrated adequate target coverage. Cervical, thoracic and GOJ regions demonstrated adequate target coverage in 57/58, 96/97 and 368/373 CBCTs with median PTV expansions of 5, 7 and 7 mm, respectively. In four patients with GOJ disease, CBCT review identified five episodes where the target volume was insufficiently covered during the treatment course. In this single institutional retrospective study, for the vast majority of patients, our institutional practice of defining PTV margins achieved satisfactory target treatment. The interfractional variations observed in patients with GOJ tumours due to target motion and variable gastric volume, highlights the role of further refinements to motion management techniques in this cohort.

Margin derivation from intrafraction patient motion of multi-target, single isocentre, brain stereotactic radiosurgery treatments.

Brain metastases are the most common intracranial malignancy and remain a substantial source of morbidity and mortality in cancer patients. Linear accelerator based stereotactic radiosurgery (SRS) is widely used and is frequently delivered by hypo-fractionnated volumetric modulated arc therapy using non-coplanar beams, where geometric accuracy and planning margins are a majorconcern. To give a practical analysis of intrafraction patient motion for multi-target, single isocentre, brain SRS treatments and to derive adapted GTV-to-PTV margins. Data of 154 lesions, spread over 85 fractions from 56 patients treated in our institution with the Varian HyperArc SRS solution was processed. Intrafraction patient motion were recorded using an Optical Surface Monitoring System during irradiation. The present study focuses on small tumor volumes, roughly equal or inferior to 1.5 , and frameless mask-based immobilization. For each treatment session, a tumor displacement vector matrix was calculated from the patient drifts as a function of time. Data were combined together into a representative treatment scenario and the dosimetric impact of GTV displacement was calculated. Recommended margins due to patient motion range between 0.3 and 1mm, depending on the distance tumor-isocentre, and the desired GTV edge dose coverage. Those values should be added quadratically with other sources of uncertainty, such as mechanical isocentre and kV-MVmisalignment. Thorough analysis of intrafraction patient motion was performed, the dosimetric impact was calculated for different scenarios, and adequate GTV-to-PTV margins were derived. These values vary according to the distance isocentre-to-GTV, as well as the desired dose coverage, and should be chosenadequately.

Dosimetric commissioning of a high-resolution CMOS 2D detector array for patient-specific QA of single-isocenter multi-target VMAT stereotactic radiosurgery.

Stereotactic radiosurgery (SRS) using the single-isocenter-multiple-target (SIMT) technique by volumetric modulated arc therapy is increasingly popular for treating multiple brain metastases. However, the complex nature of SIMT SRS necessitates rigorous patient-specific quality assurance (PSQA). This study presents a multi-institutional dosimetric commissioning of a high-resolution complementary metal oxide semiconductor (CMOS) 2D detector array, the myQA SRS device for SIMT SRS PSQA. Basic dosimetric properties such as dose-rate, field-size, energy and angular dependencies were characterized for the CMOS detectors. Additionally, gamma index analyses were performed between the measured dose and the films for nine simulated and clinical plans. The results showed that the CMOS detector was dose-rate, field-size, energy and beam-angle dependent. Specific to SIMT SRS, angular dependence on gantry rotations was invariant to couch rotations but was sensitive to off-isocenter distances. With appropriate dose calibration and angular corrections, myQA SRS showed a high dosimetric correlation with films. The average gamma index pass rates were 99.9 ± 0.03% and 99.2 ± 1.1% at 3%/2mm/10%thr(global) and 1mm/1%/10%thr(local) criteria, respectively. The average dose difference between myQA SRS and films was 0.4 ± 1.3%. In conclusion, the CMOS 2D detector array has demonstrated its potential as a reliable tool for PSQA for SIMT SRS. The excellent dosimetric agreement with the films was consistent in multiple institutions, further validating the dosimetric accuracy and reproducibility. It provides a timely alternative to film dosimetry for commissioning and quality assurance.

Replacing manual planning with automatic iterative planning for locally advanced rectal cancer VMAT treatment.

To develop and implement a fully automatic iterative planning (AIP) system in the clinical practice, generating volumetric-modulated arc therapy plans combined with simultaneous integrated boost technique VMAT (SIB-VMAT) for locally advanced rectal cancer (LARC) patients. The designed AIP system aimed to automate the entire planning process through a web-based service, includingauxiliary structuregeneration,plan creation,field configuration,plan optimization,dose calculation, andplan assessment. The system was implemented based on theEclipse scriptingapplication programming interface and an efficientiterative optimization algorithm was proposed to reduce the required iterations in the optimization process. To verify the performance of the implemented AIP system, we retrospectively selected a total of 106 patients and performed dosimetric comparisons between the automatic plans (APs) and the manual plans (MPs), in terms of dose-volume histogram (DVH) metrics, homogeneity index (HI), and conformity index (CI) for different volumes of interest. The AIP system has successfully created 106 APs within clinically acceptable timeframes. The average planning time per case was 36.8±6.5 min, with an average iteration number of 6.8(±1.1) in plan optimization. Compared to MPs, APs exhibited better performance in the planning target volume conformity and hotspot control ( ). The organs at risk (OARs) sparing was significantly improved in APs, with mean dose reductions in the femoral heads, the bone marrow, and the SmallBowel-Avoid of 0.53Gy, 1.18Gy, and 1.00Gy, respectively ( ). Slight improvement was also observed in the urinary bladder and the small bowel . Additionally, quality variation between plans from different planners was observed in DVH metrics while the APs represented better plan quality consistency. An AIP system has been implemented and integrated into the clinical treatment planning workflow. The AIP-generated SIB-VMAT plans for LARC have demonstrated superior plan quality and consistency compared with the manual counterparts. In the meantime, the planning time has been reduced by the AIP approach. Based on the reported results, the implemented AIP framework has been proven to improve plan quality and planning efficiency, liberating planners from the laborious parameter-tuning in the optimization phase.

Effects of Inc parameter on quality of VMAT radiotherapy plans for right breast cancer based on dosimetric study.

This study aimed to investigate the influence of gantry angle increment (Inc) parameters on the Monaco treatment planning system for volumetric modulated arc therapy (VMAT) in right breast cancer, and to determine the optimal Inc parameters. Twenty-three patients with right breast cancer at the Sir Run Run Shaw Hospital from August 2022 to August 2023 were retrospectively selected. Four VMAT plans were generated for each patient incorporating Inc of 10°, 20° (control group), 30°, and 40°, while the other optimization parameters and constraint functions remained constant. The D98 and conformity index were lower in the Inc30 and Inc40 groups than in the Inc20 group. As Inc increased from 10° to 30°, the irradiated dose to the ipsilateral lung, including the V20, V5, and Dmax, mean dose, gradually increased. There were no statistically significant differences in the irradiated dose to the contralateral breast, contralateral lung, heart, esophagus, and brachial plexus. The number of monitor units and control points decreased with increasing Inc. Smaller Inc values can achieve higher target coverage and lower irradiated dose to the ipsilateral lung, but will reduce delivery efficiency. Considering the plan quality and delivery efficiency, an Inc of 10° or 20° is recommended for right breast cancer VMAT plans.

Partially Ablative Body Radiation Therapy: A Widely Applicable Planning Technique for Palliation of Locally Advanced Unresectable Tumors

Patients with locally advanced, bulky, and unresectable tumors frequently exhibit frailty and endure symptomatic burdens arising from the mass effect of their tumors. Conservative approaches may often fail to provide symptomatic benefits in relatively radioresistant, slower-growing tumors such as sarcomas. A novel technique termed partially ablative body radiation therapy (PABR) administers a highly centralized ablative dose through the utilization of a simultaneous integrated boost while delivering a low and safe palliative dose to the peripheral regions of tumors. The purpose of this paper was to describe a widely applicable radiation therapy protocol in detail for the PABR technique, of which clinical results are available in previous work.7 In summary, a PABR prescription of 20 Gy in 5 fractions is applied to the planning target volume and is planned for 95% of the volume to be covered by 95% of the prescribed dose. A dose of 50 Gy is planned to the boost target volume, with an allowed maximum dose of up to 65 to 70 Gy, using volumetric modulated arc therapy. Daily Cone-Beam Computed Tomography images are used for delivery verification and imaging study. The centrally located volume exceeding 50 Gy effectively achieved the desired outcomes of symptom relief and tumor size reduction. The PABR approach is widely accessible and can be readily implemented in a routine clinical setting to address a pressing need for the challenging palliative patient cohort.